Exam 1 Flashcards
Agonist
Activate receptor and cause a favorable conformational change that activates a second messenger cascade
Antagonist
Minimal conformational change causes no second messenger cascade, no activation of receptor, prevents agonist interaction
Inverse agonist
Causes alternate conformational change and a different second messenger cascade can happen or it turns the receptor off
M1
parietal cells
M2
Nerve terminals
M3
smooth muscle
Nn
post-ganglionic cell body
Nm
skeletal muscle cells
Full agonist
maximal effect
Partial agonist
low efficacy,
reduced maximal effect,
tickles receptor,
can act as antagonist for full agonist
Antagonist efficacy
Competitive No efficacy (effect)
Competitive antagonists
Bind reversibly to the receptor
Can be overcome if increase concentration of agonist
Will not alter the maximal effect of an agonist
Most common antagonist
Dynamic (binds and releases)
Increase antagonist –> decrease apparent potency
Irreversible antagonist
Bind to the receptor in an irreversible manner
Will reduce the maximal effect of an agonist
Rare
Static
Increase irreversible –> decrease max response, and decrease apparent potency
Noncompetitive antagonists
Bind to a site adjacent to the receptor (decrease ability of receptor to be activated by agonist)
Interfere with receptor-effector coupling mechanisms (change binding site)
Have similar effect on the agonist concentration response curve as an irreversible antagonist but is reversible
Cellular response to an agonist
- A direct intercellular effect
2. Activation of an amplifying second messenger cascade
Drug Tolerance
- Receptor desensitization
- Tolerance (require higher doses to get same response)
- Resistance
Additive effect
The effect of two drugs is equal to the sum of their individual effects
Synergistic effect
The effect of two drugs i greater than the sum of their individual effects
Potentiation
A drug which alone has no effect enhances the potency of a drug which does have an effect
Receptor antagonism
A drug with no effect inhibits effect of another drug
Functional antagonism
Effect of one agonist opposes the effect of another agonist
Median effective dose
Dose of drug at which 50% of individuals demonstrate the desired therapeutic effect
Median lethal dose
Dose of drug causing death in 50% of subjects
Cytarebine (Ara-C)
Causes DNA damage, Cancer
Yondelis (Trabectedin)
Causes DNA backbone cleavage, Cancer
Prialt (Ziconotide)
Selective Blocker, Pain
Vidarabine (Ara-A)
Blocks viral DNA synthesis, antiviral agent
Eribulin
Blocks microtubule formation, Cancer
Bryostatin 1
Modulates PKC activity, failed clinical trials
Salinosporamide A (Marizomib)
Irreversibly inhibits the proteosome, Cancer
Pacleteaxel (Taxol)
Stabilizes microtubule dynamics, Cancer